Skip to main content

Advertisement

SpringerLink
Log in

Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To evaluate the long-term outcome of an OCT-guided reinjection scheme for bevacizumab treatment of macular edema (ME) due to retinal vein occlusion.

Methods

Patients with persistent ME (>250 μm) due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) received intravitreal bevacizumab 2.5 mg/0.1 ml. Visual acuity (ETDRS), ophthalmic examination and OCT were performed at baseline and at 6- to 8-week intervals. Reinjections were only performed if OCT showed persistent or recurrent ME.

Results

Sixty-one patients with a minimum follow-up of 25 weeks were included in this analysis. Mean follow-up was 60 ± 29 wks. In CRVO patients, central retinal thickness (CRT) decreased from 748 ± 265 µm to 372 ± 224 µm (p < 0.001) and visual acuity (VA) improved by 1.9 ± 3.2 lines. In BRVO patients, mean CRT decreased from 601 ± 206 µm to 386 ± 178 µm (p < 0.001) and VA improved by 1.8 ± 2.6 lines. Thirty-three percent of CRVO and 15% of BRVO patients did not show a ME recurrence for ≥25 wks at last visit. Thirty-seven percent of CRVO and 50% of BRVO patients suffered recurrences of ME within the last 25 wks, whereas 30% of CRVO and 35% of BRVO patients did not achieve a complete resolution of ME at any follow-up visit after receiving a minimum of three injections. CRVO patients with dry interval of ≥25 weeks at last visit were significantly younger, had a thinner CRT at baseline and more often had a complete resolution of ME after the first injection. In CRVO and BRVO, final VA was correlated significantly with initial VA, patients’ age and final CRT. Change of VA was correlated with change of CRT in BRVO.

Conclusions

Patients with retinal vein occlusion benefit from treatment with bevacizumab. Favourable long-term results without necessity of further injections were achieved in 33% and 15% of CRVO and BRVO patients respectively. The remaining patients needed repeated injections to treat ME recurrences. However, one third of the CRVO/BRVO patients did not improve in VA, and further injections might be discontinued in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Berker N, Batman C (2008) Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 86:245–252

    Article  PubMed  Google Scholar 

  2. Hoh AE, Schaal KB, Dithmar S (2007) Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland. Ophthalmologe 104:290–294

    Article  CAS  PubMed  Google Scholar 

  3. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751–758

    CAS  PubMed  Google Scholar 

  4. Klein MLFinkelstein D (1989) Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 107:1297–1302

    Google Scholar 

  5. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244:309–315

    Article  CAS  PubMed  Google Scholar 

  6. Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105:412–416

    Article  PubMed  Google Scholar 

  7. Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247

    Article  CAS  PubMed  Google Scholar 

  8. Hoh AE, Schaal KB, Scheuerle A, Schutt F, Dithmar S (2008) OCT-guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion. Ophthalmologe 105:1121–1126

    Article  CAS  PubMed  Google Scholar 

  9. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92:351–355

    Article  CAS  PubMed  Google Scholar 

  10. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004–1012

    Article  PubMed  Google Scholar 

  11. Schaal KB, Hoh AE, Scheuerle A, Schutt F, Dithmar S (2007) Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 104:285–289

    Article  CAS  PubMed  Google Scholar 

  12. Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429–1436

    Article  CAS  PubMed  Google Scholar 

  13. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R (2008) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147:298–306

    Article  PubMed  Google Scholar 

  14. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27–33

    Article  CAS  PubMed  Google Scholar 

  15. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518–522

    Article  CAS  PubMed  Google Scholar 

  16. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425

    Article  PubMed  Google Scholar 

  17. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606

    Article  CAS  PubMed  Google Scholar 

  18. The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491

    Google Scholar 

  19. Zhang HXia Y (2002) Analysis of visual prognosis and correlative factors in retinal vein occlusion. Zhonghua Yan Ke Za Zhi 38:98–102

    Google Scholar 

  20. Sasahara M, Mikawa A, Tajiri K, Kojima H, Saito I (2006) Visual prognosis of branch retinal vein occlusion with macular edema. Nippon Ganka Gakkai Zasshi 110:293–299

    PubMed  Google Scholar 

Download references

Acknowledgement

Supported by the Gertrud Kusen Foundation (Di2008)

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany

    Alexandra E. Hoeh, Thomas Ach, Karen B. Schaal, Alexander F. Scheuerle & Stefan Dithmar

Authors
  1. Alexandra E. Hoeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Ach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen B. Schaal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander F. Scheuerle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefan Dithmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Dithmar.

Additional information

Financial relationship: No author has any financial interest in the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoeh, A.E., Ach, T., Schaal, K.B. et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247, 1635–1641 (2009). https://doi.org/10.1007/s00417-009-1151-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-009-1151-1

Keywords

Search

Navigation